Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome
| Autor: | L. Falsetti, E. Galbignani |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Blood Glucose
Hirsutism Ethinyl Estradiol Follicle-stimulating hormone chemistry.chemical_compound Sex hormone-binding globulin Sex Hormone-Binding Globulin Acne Vulgaris Testosterone Cyproterone hirsutism biology Obstetrics and Gynecology Cyproterone acetate Alanine Transaminase Polycystic ovary Contraceptives Oral Combined Drug Combinations Cholesterol Liver Female Luteinizing hormone Polycystic Ovary Syndrome medicine.drug Adult medicine.medical_specialty Ethinylestradiol Internal medicine medicine Humans Aspartate Aminotransferases Cyproterone Acetate Triglycerides Analysis of Variance business.industry Ovary Androstenedione Androgen Antagonists Bilirubin Dehydroepiandrosterone Luteinizing Hormone Alkaline Phosphatase medicine.disease Dermatitis Seborrheic Prolactin Endocrinology Reproductive Medicine chemistry biology.protein Follicle Stimulating Hormone business |
| Zdroj: | Contraception. 42:611-619 |
| ISSN: | 0010-7824 |
| Popis: | This study evaluates the effect of therapy over a long period of time (36 cycles without interruption) with the monophasic combination containing 0.035 mg of ethinylestradiol and 2 mg of cyproterone acetate (EE35-CPA) on hormonal and clinical parameters of 66 patients with polycystic ovary syndrome (PCOS). During the administration of the pill a significant decrease in the LH/FSH ratio and in adrenal and ovarian androgens has been observed, as well as a significant increase of the Sex Hormone Binding Globulin (SHBG). The progressive decrease of the total androgenic activity explains the clinical results that have been obtained: at the 36th cycle of therapy acne disappeared in 100% of the cases, seborrea in 76.4% and hirsutism in 75%. Our results underline the need for a continuous administration without interruption of the pill with CPA in patients with clinical hyperandrogenic symptoms.This study evaluated the effect of therapy over a long period of time (36 cycles without interruption) with the monophasic combination containing 0.035 mg ethinyl estradiol and 2 mg cyproterone acetate (EE35-CPA) on hormonal and clinical parameters of 66 patients with polycystic ovary syndrome. During the administration of the pill, a significant decrease in the LH/FSH ratio and in adrenal and ovarian androgens has been observed, as well as a significant increase in sex hormone binding globulin. The progressive decrease in total androgenic activity explains the clinical results that have been obtained--at the 36th cycle of therapy, acne disappeared in 100% of the cases, seborrhea in 76.4%, and hirsutism in 75%. These results underline the need for continuous administration of the pill with CPA without interruption in patients with clinical hyperandrogenic symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|